ClinicalTrials.gg

Program

EA5

A development code.

Its studies are mostly in Myasthenia Gravis · Antiphospholipid Syndrome · Hemoglobinuria, Paroxysmal, led by Shanghai Lanyi Therapeutics.

Furthest: phase 1, since Nov 20, 20254 company-led studies, 3 open or runningNext primary completion: Sep 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Lanyi Therapeutics43 open or runningphase 1since Nov 20, 2025Nov 20, 2025Sep 30, 2027phase 1 · NCT07632976

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2025First studies: 2 phase 1 studiesFirst studyNCT07256301, NCT07256288
  2. May 28, 2026Phase 1 study in Antiphospholipid SyndromeNCT07632976 · 12 enrolled · China
  3. Sep 1, 2026Phase 1 study in Myasthenia GravisNCT07818291 · 18 planned · China

Ahead

  1. Sep 30, 2027Primary completion: phase 1 study in Antiphospholipid SyndromeNCT07632976
  2. Dec 31, 2027Primary completion: phase 1 study in Myasthenia GravisNCT07818291

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07818291Myasthenia Gravis · China1Not yet recruitingDec 31, 202718
NCT07632976Antiphospholipid Syndrome · China1Active, not recruitingSep 30, 202712
NCT07256301Hemoglobinuria, Paroxysmal · China1RecruitingAug 31, 202624
NCT07256288Healthy Volunteers · China1CompletedAug 1, 202428

How it is read

Names in the registry

  • “EA5”, 7 entries

Codes read as this program: EA5.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.